PET and CSF amyloid-β status are differently predicted by patient features: Information from discordant cases by Reimand, J et al.
PET and CSF amyloid-β status are differently predicted by patient 
features: Information from discordant cases 
 
Juhan Reimand1,2,3, Arno de Wilde1, Charlotte E. Teunissen4, Marissa Zwan1, Albert D. Windhorst5, 
Ronald Boellaard5, Frederik Barkhof5,6, Wiesje M. van der Flier1,7, Philip Scheltens1, Bart N.M. van 
Berckel5, Rik Ossenkoppele1,8, and Femke Bouwman1 
 
1 Department of Neurology & Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit 
Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. 
2 Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia 
3 Center of Radiology, North Estonia Medical Centre, Tallinn, Estonia 
4 Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije 
Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands 
5 Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit 
Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. 
6 Centre for Medical Image Computing, Medical Physics and Biomedical Engineering, UCL, United 
Kingdom 
7 Department of Epidemiology & Biostatistics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 
Amsterdam UMC, Amsterdam, the Netherlands. 
8 Lund University, Clinical Memory Research Unit, Malmö, Lund University, Sweden 
.CC-BY-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/673467doi: bioRxiv preprint first posted online Jun. 18, 2019; 
ABSTRACT 
Background: 
Amyloid-β PET and CSF Aβ42 yield discordant results in 10-20% of patients, possibly providing unique 
information. Although the predictive power of demographic, clinical, genetic and imaging features for 
amyloid-positivity has previously been investigated, it is unknown whether these features differentially 
predict amyloid-β status based on PET or CSF, or whether this differs by disease stage.  
Methods: 
We included 768 patients (subjective cognitive decline (SCD, n=194), mild cognitive impairment (MCI, 
n=127), dementia (AD and non-AD, n=447) with amyloid-β PET and CSF Aβ42 measurement within one 
year. 97(13%) patients had discordant PET/CSF amyloid-β status. We performed parallel random forest 
models predicting separately PET and CSF status using 17 patient features (demographics, APOE4 
positivity, CSF (p)tau, cognitive performance, and MRI visual ratings) in the total patient group and 
stratified by syndrome diagnosis. Thereafter, we selected features with the highest variable importance 
measure (VIM) as input for logistic regression models, where amyloid status on either PET or CSF was 
predicted by (i) the selected patient feature, and (ii) the patient feature adjusted for the status of the 
other amyloid modality. 
Results: 
APOE4, CSF tau and p-tau had highest VIM for PET and CSF in all groups. In the amyloid-adjusted logistic 
regression models, p-tau was a significant predictor for PET-amyloid in SCD (OR=1.02[1.01-1.04], 
pFDR=0.03), MCI (OR=1.05[1.02-1.07], pFDR<0.01) and dementia (OR=1.04[1.03-1.05], pFDR<0.001), but not 
for CSF-amyloid. APOE4 (OR=3.07[1.33-7.07], punc<0.01) was associated with CSF-amyloid in SCD, while it 
was only predictive for PET-amyloid in MCI (OR=9.44[2.93,30.39], pFDR<0.01). Worse MMSE scores 
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(OR=1.21[1.03-1.41], punc=0.02) were associated to CSF-amyloid status in SCD, whereas worse memory 
(OR=1.17[1.05-1.31], pFDR=0.02) only predicted PET positivity in dementia. 
Conclusion : 
Amyloid status based on either PET or CSF was predicted by different patient features and this varied by 
disease stage, suggesting that PET-CSF discordance yields unique information. The stronger associations 
of both APOE4 carriership and worse memory z-scores with CSF-amyloid in SCD suggests that CSF-amyloid 
is more sensitive early in the disease course. The higher predictive value of CSF p-tau for a positive PET 
scan suggests that PET is more specific to AD pathology. These findings can influence the choice between 
amyloid biomarkers in future studies or trials. 
  
.CC-BY-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/673467doi: bioRxiv preprint first posted online Jun. 18, 2019; 
INTRODUCTION: 
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β plaques, which has been 
shown to occur decades before symptom onset (1,2). Amyloid-β pathology can be detected in vivo by 
positron emission tomography (PET) using amyloid-β radiotracers such as [11C]Pittsburgh compound-B 
(PIB), [18F]Florbetapir, [18F]Florbetaben or [18F]Flutemetamol allows to directly visualize fibrillary amyloid-
β deposits in brain tissue (3–6). Alternatively, Aβ42 levels in cerebrospinal fluid (CSF) reflect the 
concentration of soluble amyloid-β, which correlates with cerebral amyloid-β depositions (7). PET and CSF 
have been included as equal alternatives into diagnostic criteria for both research (2,8,9) and clinical 
practice (10–12). However, it has been repeatedly shown that in 10-20% of patients these modalities yield 
conflicting results (13–15). This discordance may include valuable information on underlying clinical or 
neuropathological differences (16). 
 
A combination of various patient features has previously been demonstrated to predict amyloid-β 
positivity based on PET and/or CSF (17,18). In particular, a combination of demographic information, APOE 
ε4 carriership, neuropsychological tests, and magnetic resonance imaging (MRI) measures was effective 
in predicting amyloid-β status (19). Additionally, CSF tau and p-tau have been shown to be predictive of 
amyloid PET status (20). So far it has not been investigated whether the predictive ability of patient 
features for amyloid-β pathology differs when detected by PET or by CSF. If these two modalities would 
provide partially independent information about the underlying pathology, then this could be reflected 
by the differences in predictive patterns for the two modalities. Additionally, as it has been suggested that 
CSF might be able to detect amyloid-β depositions earlier (21), it is possible that the relative predictive 
contribution of a patient feature changes throughout the course of Alzheimer’s disease. Therefore, we 
investigate the unique information provided by the PET-CSF discordant population using the predictive 
patterns for amyloid PET and CSF in (i) the total patient group and (ii) stratifying by syndrome diagnosis. 
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Exploring this allows us to gain insight in the clinical and neurobiological factors related to discordant 
results between amyloid-β PET and CSF and ultimately about the underlying neuropathological processes 
during the disease course of AD. 
 
METHODS: 
Study Population 
We retrospectively included 777 patients, who had visited our tertiary memory clinic between 2005 and 
2017 and had undergone both CSF Aβ42 analysis and amyloid-β PET within one year. We excluded nine 
patients that did not pass PET imaging quality control. Patients were screened according to the 
standardized protocol of the Amsterdam Dementia Cohort (22,23). This includes a clinical and 
neuropsychological evaluation, APOE genotyping, MR imaging and a lumbar puncture for CSF analysis. 
Patient diagnosis was determined during a multidisciplinary meeting, according to international guidelines 
(10,11,24–32).  
 
Neuropsychological testing 
Subjects underwent extensive neuropsychological testing as part of their diagnostic process. Mini-Mental 
State Examination (MMSE) scores were used to measure global cognition. In addition, five cognitive 
domains were assessed (33). We used the visual association test (VAT), total immediate recall, and the 
Dutch version of the Rey Auditory Verbal Learning test (delayed recall) to assess memory. Language was 
assessed by VAT naming and category fluency (animals). The Trail-Making Test (TMT) part A, Digit Span 
forwards and the Stroop test I and II were used for attention. Executive functioning was assessed by TMT 
B, Digit Span backwards, Stroop test III, the Frontal Assessment Battery, and the Dutch version of the 
Controlled Oral Word Association Test (letter fluency). Finally, we assessed visuospatial functioning by 
Visual Object and Space Perception battery: tests incomplete letters, dot counting and number location.  
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 For every test, we derived Z-scores using the mean and standard deviation values from a group of healthy 
controls (n = 360) (33). TMT-A, TMT-B and Stroop Test scores were log-transformed to account for the 
non-normal distribution of the data and multiplied by -1 so that lower scores would indicate worse 
performance. In case TMT B was aborted and TMT A was available (n = 132), we estimated the TMT B 
score using the multiplication of TMT A score with mean TMT B/A score ratio from the respective 
diagnostic group (34). Thereafter, based on available tests we used z-scores to compile a composite score 
for each of the five cognitive domains. 
 
CSF 
CSF was obtained by lumbar puncture between L3/4, L4/5 or L5/S1 intervertebral space, using a 25-gauge 
needle and a syringe (35). The samples were collected in polypropylene microtubes and centrifuged at 
1800g for 10min at 4°C. Thereafter, the samples were frozen at -20 °C until manual analyses of Ab42, tau 
and p-tau were performed using sandwich ELISAs [Innotest assays: β-amyloid1-42, tTAU-Ag and 
PhosphoTAU-181p; Fujirebio (formerly Innogenetics)] at the Neurochemistry Laboratory of the 
Department of Clinical Chemistry of VUmc. As the median CSF Aβ42 values of our cohort have been 
gradually increasing over the years (36), we determined CSF amyloid-β status using Aβ42 values that had 
been adjusted for the longitudinal upward drift. We used a uniform cut-off of 813 pg/mL to dichotomize 
CSF data, as continuous measures were not available for PET imaging (37).  
 
PET 
Amyloid-β PET scanning is not part of standard diagnostic process in the Amsterdam Dementia Cohort. 
Patients underwent an amyloid-β PET for research purposes in the vast majority (38–43) or otherwise in 
case of a diagnostic dilemma. Amyloid-β PET scans were performed using the following PET scanners: 
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ECAT EXACT HR+ scanner (Siemens Healthcare, Germany) and Gemini TF PET/CT, Ingenuity TF PET-CT and 
Ingenuity PET/MRI (Philips Medical Systems, the Netherlands). We included PET scans using four different 
radiotracers: [18F]Florbetaben (38,43) (n=322, 42%), [11C]PIB (40–42) (n=271, 35%), [18F]Flutemetamol (44) 
(n=151, 20%), and [18F]Florbetapir (39) (n=24,  3%). PET scans were rated as positive or negative based on 
visual read by an expert nuclear medicine physician (BvB). PET scans were performed, on average, within 
54 (±75) days of the lumbar puncture. 
 
MRI 
The acquisition of MRI scans has been extensively described previously (23). During the period of 2005 to 
2017, the following scanners have been used: Discovery MR750 and Signa HDXT (both GE Medical 
Systems, USA); Ingenuity TF PET/MR (Philips Medical Systems, The Netherlands); Titan (Toshiba Medical 
Systems, Japan); Magnetom Impact and Sonata (Siemens Healthcare, Germany). The MRI protocol 
included 3D T1-weighted, T2-weighted, fluid-attenuated inversion recovery (FLAIR), gradient-echo T2* 
and/or susceptibility weighted imaging sequences. The scans were visually assessed by a neuroradiologist 
on three different image planes. Parietal atrophy was rated using the posterior cortical atrophy (PCA) 
scale (45), medial temporal atrophy using the medial temporal lobe atrophy (MTA) scale (46) and the 
extent of white matter hyperintensities according to the Fazekas scale (47). MTA and PCA scores were 
scored separately for right and left and averaged thereafter. In addition, the scans were assessed for the 
existence of lacunes and microbleeds.  
 
Patient groups 
We stratified the patients based on syndrome diagnosis: subjective cognitive decline (SCD, n=194 (29%)) 
(48), mild cognitive impairment (MCI, n=127 (17%)), and dementia (n=447 (58%)). Within the dementia 
group, 309 (69%) patients had the diagnosis of Alzheimer’s disease, 66 (15%) a diagnosis within the 
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frontotemporal dementia spectrum, 22 (5%) dementia with Lewy bodies, 6 (1%) vascular dementia and 
44 (10%) other dementia syndromes. To reflect the information provided to the models in our analysis, 
we present patient group characteristics based on the binarized amyloid-β status on PET and CSF: 
concordantly positive (PET+/CSF+) or negative (PET-/CSF- for amyloid-β pathology, or discordantly 
positive amyloid-β status based on PET (PET+/CSF-) or CSF (PET/CSF+).  
 
Statistical Analysis 
Statistical analysis was performed using R software (Version 3.4.4) (49). When presenting our study 
population by binarized PET/CSF status groups, we compared patient features using Chi-squared tests, 
two samples t-tests, Wilcoxon Rank-Sum tests and linear regression models with Bonferroni correction 
for group-wise testing.  Cognitive scores were compared while adjusting for age, sex, education and 
syndrome diagnosis. 
 
All subsequent analyses were performed in the total patient group as well as in the syndrome diagnosis 
groups of SCD, MCI and dementia. We first summarized the relative predictive power of every variable in 
predicting PET and CSF amyloid-β status using random forest modelling. As classifier models are affected 
by missing data, we accounted for missing values using multiple imputations (with 25 imputations and 5 
iterations) (Supplementary Table 1). For each of the imputed dataset, we ran two conditional random 
forest models (50,51), predicting separately PET and CSF status using various patient features associated 
with Alzheimer’s disease (17–19). As predictors, we selected demographic information (age, sex, 
education), biomarkers (APOE ε4 positivity, CSF tau and p-tau), cognitive measures (MMSE; z-scores for 
memory, language, attention, executive, visuospatial), and MRI scores (MTA, PCA, Fazekas scale, the 
presence of lacunes and microbleeds). We used the area-under-the-curve (AUC)-based permutation 
variable importance measure (VIM) to estimate the relative predictive power for every patient feature. 
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This measure was selected because of its higher accuracy in datasets with an unbalanced outcome class 
(52) and we expected this to be especially helpful in the SCD group with a low prevalence of amyloid-β 
positivity. Accuracy, sensitivity and specificity of the random forest models were evaluated using the mean 
out-of-bag error estimates. Using this method, the performance of every tree in the random forest model 
is evaluated on the approximately 37% of observations that are not used for its training (53). 
 
For the second stage of the analysis, we selected patient features based on their predictive value in the 
random forest models. Similar to a previous study (19), we included patient features when their median 
VIM over the 25 random forests models for predicting either PET or CSF was higher than the median VIM 
of all the features for the patient group. First, using two sample t-testing of 1000x bootstrapped samples 
with replacement, we compared the VIM of every selected patient feature between the parallel random 
forest models predicting amyloid-β PET and CSF status. Secondly, to determine the unadjusted predictive 
power of these patient features, we performed bivariate logistic regression models with either PET or CSF 
positivity as the outcome and the selected patient features as predictors. Thirdly, to investigate the added 
predictive value of a patient feature to the other amyloid-β modality, we performed multivariable logistic 
regression models, with either PET or CSF positivity as the outcome and the selected patient feature with 
the status of the other amyloid-β modality as predictors. 
 
We calculated the odds ratios (OR) with corresponding 95% confidence intervals for every patient feature 
both in the original dataset and in the 25x imputed datasets. Non-overlapping confidence intervals were 
considered significantly different. We used the False discovery rate (FDR) correction with a significance 
level of 0.05 to account for multiple testing (54). 
 
RESULTS: 
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Overview of features 
Patient characteristics grouped by PET/CSF status are summarized in Table 1 and CSF Aβ42 levels shown 
in Figure 1. 32 patients (4%) were discordantly amyloid-β positive based on PET and 65 (8%) based on CSF. 
In general, the PET+CSF+ group showed a higher proportion of APOE ε4 carriers, more AD-like CSF 
markers, MRI features, and lower cognitive scores compared to PET-CSF- group. CSF tau and p-tau were 
lower in both PET-CSF- and PET-CSF+ groups, compared to PET+CSF- and PET+CSF+. The PET-CSF- group 
contained a lower proportion of APOE ε4 carriers and better cognitive scores than patients in the 
discordant groups. 
 
Patient feature selection 
We performed random forest modelling to (i) select patient features based on overall VIM for 
multivariable logistic regression models and (ii) compare the VIM between models predicting PET and CSF 
amyloid-β status. Summarized VIM values over the 25 random forest models (one with each set of imputed 
data) are shown in Figure 2. Out-of-bag accuracy, sensitivity and specificity rates for the random forest 
models are reported in Supplementary Table 2. APOE ε4 positivity was the most important predictor for 
amyloid-β positivity in the total patient group for both PET (VIM=0.28±0.14 (mean VIM*100 ± standard 
deviation)) and CSF (VIM=0.31±0.19, PET/CSF VIM difference: p=0.51). CSF tau was similarly important 
when predicting PET (VIM=0.06±0.03) or CSF (VIM=0.06±0.03, p=0.51), but CSF p-tau was a more 
important predictor for PET (VIM=0.12±0.03) compared to CSF (VIM=0.03±0.01, p<0.001). 
 
Subsequently, we stratified for syndrome diagnosis. In SCD, APOE ε4 positivity was a stronger predictor 
for CSF (VIM=5.06±0.63) than PET (VIM=1.19±0.18, p<0.001), whereas CSF p-tau was more associated 
with PET (VIM=1.89±0.29) than CSF amyloid-β status. (VIM=1.44±0.18, p<0.001). Additionally, MMSE 
(VIM=0.37±0.17) and memory score (VIM=0.66±0.18) had a stronger association with CSF than PET (both 
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p<0.001). CSF tau was equally important for predicting PET (VIM=5.47±0.36) or CSF amyloid-β status 
(VIM=5.24±0.38, p=0.13). In contrast to the findings in SCD, in MCI, APOE ε4 carriership was a stronger 
predictor for PET (VIM=7.07±0.69) than for CSF (VIM=6.31±0.56, p<0.01). Moreover, CSF tau and p-tau 
were more important for predicting PET (respectively VIM=6.56±0.42; and VIM=4.90±0.38) than for CSF 
amyloid-β status (VIM=3.20±0.25, p<0.001; and VIM=2.84±0.21, p<0.001). In dementia, CSF p-tau was 
more predictive of PET (VIM=1.60±0.32) than CSF (VIM=0.92±0.22, p<0.001), but CSF tau was a stronger 
predictor for CSF (VIM=0.27±0.07) than for PET amyloid-β status (VIM=0.17±0.04, p<0.001). Both PET 
(VIM=0.93±0.34) and CSF (VIM=0.97±0.35, p=0.49) had a strong association to APOE ε4 carriership. Finally, 
visuospatial (VIM=0.37±0.13) and memory (VIM=0.08±0.03) scores were more important for predicting 
PET positivity (both p<0.001). 
 
We verified the predictive ability of the selected patient features with bivariate logistic regression models 
for PET and CSF status (Table 2; all possible models in Supplementary Table 3). The bivariate models 
largely confirmed the feature selection of the random forest procedure, as APOE ε4, CSF tau and CSF p-
tau were consistently significant predictors in all groups. In the total group and dementia, most of the 
patient features selected based on the random forest models were significant predictors.  
 
Amyloid-adjusted multivariable logistic regression models 
We investigated the added predictive value of the selected patient features to the other amyloid-β 
modality with multivariable logistic regression models (Table 3; all possible models in Supplementary 
Table 4). We assumed that if PET and CSF would truly provide equal information about amyloid status, 
additional patient features should never be significant predictors in these models, as the other amyloid 
status would already provide sufficient predictive power. However, if a patient feature added significant 
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information, this would show a stronger association between the feature and the predicted amyloid-β 
modality. 
 
The following odds ratios are adjusted for the status of the other amyloid modality. In the total group 
increased levels of CSF p-tau (odds ratio (OR)=1.04[95% confidence interval:1.03,1.05] vs 
OR=1.01[1.00,1.02]) and tau (OR=1.003[1.003,1.004] vs OR=1.001[1.000,1.002]) were more strongly 
associated with PET than CSF. In SCD, increased levels of CSF p-tau (OR=1.02[1.01,1.04], p=0.03) and tau 
(OR=1.003[1.001,1.005], p=0.03) were predictive of only PET, but not CSF positivity (respectively, 
OR=1.01[1.00,1.03], p=0.42 and OR=1.002[1.000,1.003], p=0.37). APOE ε4 carriership 
(OR=3.07[1.33,7.07], punc<0.01, pFDR=0.07) and lower MMSE scores (OR=1.21[1.03,1.41], punc=0.02, 
pFDR=0.11) showed a predictive trend towards amyloid-β status based on CSF, but not on PET (respectively, 
OR=1.54[0.62,3.78], p=0.56 and  vs OR=0.93[0.80,1.10], p=0.61). In MCI, a positive PET scan was more 
strongly predicted by APOE ε4 carriership (OR=9.44[2.93,30.39], p<0.01 vs OR=1.85(0.58,5.92), p=0.60 for 
CSF status), and by increased levels of CSF p-tau (OR=1.05[1.02,1.07], p<0.01 vs 0.99[0.98,1.01], p=0.70) 
and tau (OR=1.008[1.004,1.012], p<0.001 vs OR=0.999[0.997,1.001], p=0.65). Finally, in dementia, PET 
status had a stronger association with increased levels of CSF p-tau (OR=1.04[1.03,1.05], p<0.001 vs 
OR=1.01[1.00,1.03], p=0.19 for CSF), tau (OR=1.003[1.002,1.004], p<0.001 vs OR=1.001[1.000,1.002], 
p=0.13), and with a worse performance in memory (OR=1.18[1.05,1.32], p=0.02 vs OR=1.00[0.89,1.11], 
p=0.95), and visuospatial ability (OR=1.32[1.10,1.59], p=0.02 vs OR=0.99[0.84,1.17], p=0.95) than CSF 
amyloid-β status. APOE ε4 carriership was similarly associated with both PET (OR=2.22[1.20,4.09], p=0.03) 
and CSF (OR=2.00[1.06,3.78], punc=0.03, pFDR=0.09). No patient feature showed a higher association with 
CSF in dementia. 
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DISCUSSION: 
We investigated the predictive patterns of various patient features for amyloid-β status based on PET or 
CSF to determine (i) whether these features have a different association with PET or CSF and (ii) whether 
this differs per disease stage. We found significant differences in the predictive strength of patient 
features for amyloid-β status based on PET or CSF. For example, CSF tau, and, especially, CSF p-tau 
consistently showed a stronger association with amyloid-β status on PET. Additionally, the differential 
predictive pattern was influenced by the extent of cognitive impairment, as CSF tau was more important 
in SCD and MCI, while CSF p-tau became more important in the stage of dementia. Moreover, APOE ε4 
carriership was more predictive towards CSF status in SCD, whereas it was more predictive towards PET 
in MCI. These findings suggest that PET and CSF do not provide identical information about the stage of 
Alzheimer’s disease.  
 
The idea to study differences in the predictive strength of patient features for PET/CSF amyloid-β status 
was based on the differences in characteristics of patients with discordant amyloid-β biomarkers, which 
have been theorized to be caused by various factors. Possible explanations for the discordance include 
individual variances in CSF Aβ42 production (55), the composition of amyloid-β plaques (56), differences 
in the structure of Aβ fibrils (57), or a variety of technical issues (58,59), including the variability in cut-off 
values for CSF Aβ42 (14). It has also been proposed that in the earliest stages of amyloid-β accumulation 
CSF Aβ42 analysis might be more sensitive, as the decrease in the concentration of soluble isoforms might 
precede fibrillar amyloid-β plaque deposition detectable by PET (21). The differences in the predictive 
pattern found here in relation to other biological variables, such as APOE genotype and (p)tau 
concentrations, imply that the existence of PET/CSF discordance may not only be due to technical 
variation, but a reflection of the differences in biological substrate between the modalities. This could also 
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have an effect for future practice in AD research as well as patient care, as the two modalities are currently 
used as equal alternatives (2,11). 
 
We observed that CSF p-tau and tau had a stronger association to amyloid-β based on PET compared to 
CSF. If we assume that CSF is a more sensitive modality for amyloid-β pathology, then the weaker 
association with tau could be explained by CSF Aβ42 capturing an earlier stage amyloid-β preceding tau 
pathology. This was reflected by the predictive patterns in the multivariable logistic regression models: 
when predicting PET status by CSF status, CSF (p)tau adds information about the added burden of disease 
(including advancing from CSF+PET- to CSF+PET+). When predicting CSF amyloid-β positivity, however, the 
existence of amyloid-β pathology on PET already provides sufficient predictive power, of subjects already 
having reached a later stage in amyloid deposition. Overall, this finding is in accordance with previous 
work, indicating that PET detects more advanced stages of AD pathology (60). Although CSF tau and p-tau 
have been shown to be highly correlated (61), the results of the random forest models imply that CSF tau 
is more predictive towards amyloid-β pathology in SCD and MCI, whereas CSF p-tau is more predictive in 
dementia. This finding might be caused by wider neuronal death preceding the release of phosphorylated 
tau, although previous work seems to suggest that levels of CSF p-tau decrease in the later stages of AD 
(62–64). Another possible explanation is that this finding is caused by the greater specificity of p-tau for 
AD pathology (65), as our cohort also included amyloid-positive patients diagnosed with non-AD 
dementia, possibly due to secondary amyloid pathology. 
 
Although we focus on the relative differences between PET and CSF, it should be emphasized that in the 
majority of cases these two modalities contain similar information. This was demonstrated by many of 
the selected patient features having some predictive power for amyloid-β pathology for both PET and CSF. 
Of them, the biological factors APOE ε4 carriership, CSF tau, and p-tau were most consistent in having 
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significant predictive ability amyloid-β status irrespective of the modality. These findings are not 
unexpected, as APOE ε4 carriership (17,66,67) and tau pathology (2,68) are widely known to have a strong 
connection to amyloid-β pathology in Alzheimer’s disease. Cognitive measures and MRI visual reads 
showed overall a smaller predictive value towards amyloid-β status, being in concordance with the theory 
that they show changes downstream of amyloid and tau pathology (69). 
 
The main strength of our study is the large number of patients with both amyloid-β modalities from a 
well-characterized cohort. Our study also has several weaknesses. First, due to the stratification by 
syndrome diagnoses, the outcome of amyloid-β positivity was not equally prevalent. Although we used 
an AUC-based importance measure that has been shown to be more effective with an unbalanced 
outcome class (52), there was still a notably low sensitivity in the SCD group. This could theoretically 
influence the outcome of the random forest models, although we found comparable results when using 
logistic regression models. Second, the included patients underwent amyloid-β PET scans with four 
different radiotracers, allowing for variability in thresholds for amyloid-β positivity. However, this effect 
is likely reduced by all of the PET scans being visually rated by the same experienced nuclear medicine 
physician. Third, as continuous measures for PET-imaging were not available, we dichotomized CSF Aβ42 
values, causing some loss of information. Fourth, this patient group did not have CSF Aβ40 values available, 
which have been shown to correct for the individual variation in the production of amyloid-β (70,71). 
 
Our findings can be summarized by a hypothetical model highlighting the relative predictive power of 
patient features towards amyloid-β status based on PET and CSF (Figure 3). This model supports previous 
work, suggesting that CSF might be more sensitive in the early stages of amyloid-β pathology, whereas 
PET status might be more specific to later stages of amyloid-β accumulation. Although the modalities show 
similar information in the majority of cases, this could have implications for future research and clinical 
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trials. For example, if aiming to capture the earliest stage of amyloid-β pathology, CSF might be preferred 
over PET. On the contrary, if high confidence of significant amyloid-β pathology is required, PET could be 
the modality of choice. 
 
CONCLUSION: 
We demonstrated that although various patient features have general predictive value towards amyloid-
β status, there are finer differences revealed by discordant cases between the predictive pattern for 
amyloid-β status based on PET and CSF. This indicates that PET-CSF discordance includes valuable 
information on underlying clinical and neuropathological differences. 
 
DECLARATIONS: 
The local medical ethics committee of VU University Medical Center has approved a general protocol for 
biobanking and using the clinical data for research purposes. The data used in this study are not publicly 
available but may be provided upon reasonable request. The Alzheimer Center Amsterdam is supported 
by Alzheimer Nederland and Stichting VUmc fonds. Research performed at the Alzheimer Center 
Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The clinical 
database structure was developed with funding from Stichting Dioraphte. WvdfF was recipient of 
ZonMW-Memorabel ABIDE (project No 733050201), a project in the context of the Dutch Deltaplan 
Dementie. WvdF holds the Pasman chair. The funding sources had no involvement in the writing of this 
article or in the decision to submit it for publications. JR acknowledges Prof Sergei Nazarenko, the North 
Estonia Medical Centre and the International Atomic Energy Agency for their contribution to his 
professional development. 
 
.CC-BY-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/673467doi: bioRxiv preprint first posted online Jun. 18, 2019; 
AUTHORS’ CONTRIBUTIONS: 
JR, RO, and FBo conceived the study, designed the protocol, analyzed/interpreted data, drafted the 
manuscript. JR performed statistical analysis. RO, FBo, and PS provided overall study supervision. AdW, 
CET, MZ, ADW, RB, FBa, WMvdF, PS, BNMvB had a major role in the acquisition of data, and critically 
revised and edited the manuscript for intellectual content. All authors read and approved the final 
version of the manuscript. 
 
FIGURE CAPTIONS: 
Figure 1. CSF Aβ42 values by PET/CSF amyloid status groups in SCD, MCI and dementia.  
Horizontal line indicates the cut-off of 813 pg/mL used for dichotomization of CSF-amyloid.  
 
Figure 2. Relative predictive power of patient features for amyloid PET and CSF status 
AUC-based variable importance (VIM) from 25 random forest models predicting PET status and 25 models 
from predicting CSF status are plotted.  P-values (*** - p<0.001, ** - p<0.01, * - p<0.05,  ns - non-
significant) indicate the bootstrapped difference of VIM values between models predicting PET and CSF 
status.  
 
Figure 3. Hypothetical model for relative predictive strength of patient features toward PET and CSF 
amyloid status 
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Line location on the y-axis indicates the relative strength of the association between the patient feature 
and status of the amyloid-ꞵ modality.  Line thickness indicates the overall predictive strength of the 
patient feature for amyloid status based on both PET and CSF. 
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Table 1. Patient groups by PET/CSF amyloid status  
 
Education is staged by Verhage classification (1-7). Lacune and microbleed positivity is scored, if at least one is 
present. MTA - medial temporal lobe atrophy scale. PCA - posterior cortical atrophy scale.   
 
PET-CSF- PET+CSF- PET-CSF+ PET+CSF+ 
DEMOGRAPHICS: 
    
N (%) 315 (41) 32 (4) 65 (8) 356 (46) 
Sex, male (%) 211 (67)D 17 (53) 41 (63) 192 (54)A 
Age, years (mean (SD)) 62.8 (7.7) 65.0 (7.7) 62.4 (9.0) 63.7 (7.3) 
Education (median [IQR]) 5 [4, 6] 5 [4, 6] 5 [4, 6] 5 [4, 6] 
SYNDROME DIAGNOSIS (%): 
        
SCD 136 (43) 10 (31) 20 (31) 28 (8) 
MCI 55 (18) 8 (25) 9 (14) 55 (15) 
AD dementia 28 (9) 11 (34) 17 (26) 253 (71) 
non-AD dementia 96 (31) 3 (9) 19 (29) 20 (6) 
BIOMARKERS: 
        
CSF-PET difference, days (mean (SD)) 61 (75) 54 (70) 74 (84) 58 (67) 
CSF Aꞵ42, pg/mL (median [IQR]) 1134 [989, 1275]BCD 875 [832, 959]ACD 674 [625, 741]ABD 615 [537, 688]ABC 
CSF tau, pg/mL (median [IQR]) 277 [207, 375]BD 468 [324, 716]AC 287 [174, 501]BD 609 [403, 845]AC 
CSF p-tau, pg/mL (median [IQR]) 44 [35, 54]BD 67 [50, 90]AC 41 [28, 61]BD 82 [58, 103]AC 
APOE E4 positivity (%) 84 (28)BCD 18 (60)A 32 (52)A 238 (70)A 
COGNITION:         
MMSE (mean (SD)) 26 (3)BD 24 (5)A 25 (4) 23 (4)A 
Memory z-score (mean (SD)) -1.39 (2.27)BD -3.14 (2.73)A -2.20 (2.96) -3.34 (2.76)A 
Language z-score (mean (SD)) -0.65 (1.29) -0.95 (1.48) -1.44 (2.27)C -1.03 (1.83)D 
Attention z-score (mean (SD)) -0.69 (1.09)D -0.82 (1.08) -0.98 (1.02) -1.10 (1.21)A 
Executive z-score  (mean (SD)) -1.01 (1.38)D -1.39 (1.55) -1.27 (1.32) -1.53 (1.40)A 
Visuospatial z-score (mean (SD)) -0.34 (1.18)D -1.04 (1.90) -0.90 (1.70) -1.36 (2.40)A 
MRI:         
MRI-amyloid difference, days (mean (SD)) 16 (50)C  35 (60) 44 (78)AD 14 (45)C 
MTA (median [IQR]) 0.5 [0.0, 1.0]D 0.5 [0.0, 1.0] 0.5 [0.0, 1.8] 1.0 [0.5, 1.5]A 
PCA (median [IQR]) 1.0 [0.0, 1.1]D 1.0 [1.0, 1.0] 1.0 [0.0, 1.4]D 1.0 [1.0, 2.0]AC 
Fazekas (median [IQR]) 1.0 [0.0,1.0] 1.0 [0.8, 1.0] 1.0 [0.0, 2.0] 1.0 [0.0, 1.0] 
Lacune positivity (%) 14 (6) 0 (0) 7 (11) 17 (7) 
Microbleed positivity (%) 31 (13) 4 (15) 4 (7) 54 (21) 
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A, B, C, D indicate significant difference (p < 0.05) from other groups:    
 A - difference from PET-CSF-  
 B - difference from PET+CSF-  
 C - difference from PET-CSF+  
 D - difference from PET+CSF+  
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Table 2. Predictive value of patient features for amyloid status based on PET or CSF 
 
*** - p<0.001, ** - p<0.01, * - p<0.05. P-values indicate the significance of the patient feature in the model. Uncorrected p-values and corrected p-values are reported per model, additionally 
corrected p-values for imputed data. False discovery rate (FDR) correction was performed for multiple comparisons. Cognitive scores have been multiplied by -1, therefore lower scores usually 
indicate higher odds ratios for amyloid positivity. 
 
 
 TOTAL SCD MCI DEMENTIA 
     Imputed    Imputed    Imputed    Imputed 
Predictor 
Out- 
come 
Odds ratio  
(95% CI) 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR 
Odds ratio 
(95% CI) 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR 
Odds ratio 
(95% CI) 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR 
Odds ratio 
(95% CI) 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR 
Age 
PET 1.02(1.00,1.04)   1.02(1.00,1.04)  1.06(1.01,1.12) *  1.06(1.01,1.12)  0.96(0.92,1.00)   0.96(0.92,1.00)       
CSF 1.01(0.99,1.03)   1.01(0.99,1.03)  1.04(1.00,1.09)   1.04(1.00,1.09)  0.96(0.92,1.00)   0.96(0.92,1.00)       
Sex, F 
PET      1.64(0.81,3.36)   1.64(0.81,3.36)  2.45(1.14,5.26) *  2.45(1.14,5.26)  1.70(1.13,2.53) ** * 1.70(1.13,2.53) * 
CSF      1.91(0.99,3.69)   1.91(0.99,3.69)  2.01(0.94,4.28)   2.01(0.94,4.28)  1.40(0.93,2.12)   1.40(0.93,2.12)  
Education 
PET 1.06(0.94,1.19)   1.07(0.95,1.20)            1.28(1.08,1.52) ** ** 1.30(1.10,1.53) ** 
CSF 1.04(0.93,1.17)   1.05(0.94,1.18)            1.29(1.08,1.54) ** ** 1.30(1.09,1.54) ** 
APOE E4 
PET 4.72(3.46,6.44) *** *** 4.57(3.34,6.24) *** 2.97(1.42,6.20) ** * 2.97(1.42,6.19) * 14.55(6.08,34.82) *** *** 13.43(5.62,32.11) *** 3.63(2.39,5.50) *** *** 3.51(2.30,5.34) *** 
CSF 4.60(3.36,6.28) *** *** 4.46(3.26,6.12) *** 3.82(1.90,7.70) *** *** 3.75(1.86,7.57) ** 8.28(3.70,18.54) *** *** 7.76(3.49,17.27) *** 3.68(2.39,5.69) *** *** 3.59(2.33,5.53) *** 
CSF tau 
PET 
1.005  
(1.004,1.006) 
*** *** 
1.005  
(1.004,1.006) 
*** 
1.004  
(1.002,1.006) 
*** *** 
1.004  
(1.002,1.006) 
*** 
1.008  
(1.005,1.011) 
*** *** 
1.008  
(1.005,1.011) 
*** 
1.004  
(1.003,1.005) 
*** *** 
1.004  
(1.003,1.005) 
*** 
CSF 
1.004  
(1.003,1.005) 
*** *** 
1.004  
(1.003,1.005) 
*** 
1.003  
(1.002,1.005) 
*** *** 
1.003  
(1.002,1.005) 
** 
1.003  
(1.002,1.005) 
*** *** 
1.003  
(1.002,1.005) 
*** 
1.004  
(1.003,1.004) 
*** *** 
1.003  
(1.002,1.004) 
*** 
CSF p-tau 
PET 1.05(1.04,1.06) *** *** 1.05(1.04,1.06) *** 1.04(1.02,1.05) *** *** 1.04(1.02,1.05) *** 1.05(1.03,1.07) *** *** 1.05(1.03,1.07) *** 1.05(1.04,1.06) *** *** 1.05(1.04,1.06) *** 
CSF 1.04(1.03,1.04) *** *** 1.04(1.03,1.04) *** 1.03(1.01,1.04) *** *** 1.02(1.01,1.04) ** 1.03(1.01,1.04) *** *** 1.03(1.01,1.04) *** 1.04(1.03,1.05) *** *** 1.04(1.03,1.05) *** 
MMSE 
PET 1.20(1.15,1.25) *** *** 1.19(1.14,1.24) *** 1.03(0.89,1.19)   1.02(0.88,1.18)            
CSF 1.20(1.15,1.25) *** *** 1.19(1.14,1.25) *** 1.15(1.01,1.31) *  1.13(1.00,1.29)            
Memory 
PET 1.36(1.27,1.47) *** *** 1.36(1.27,1.46) *** 1.13(0.82,1.55)   1.14(0.83,1.56)  1.26(1.02,1.57) *  1.25(1.00,1.54)  1.20(1.10,1.30) *** *** 1.20(1.10,1.31) *** 
CSF 1.32(1.23,1.42) *** *** 1.32(1.23,1.42) *** 1.23(0.92,1.64)   1.22(0.91,1.62)  1.16(0.95,1.42)   1.12(0.92,1.38)  1.14(1.05,1.24) ** ** 1.15(1.06,1.26) ** 
Language 
PET           0.38(0.18,0.81) * * 0.44(0.21,0.95)       
CSF           0.71(0.39,1.27)   0.71(0.39,1.29)       
Executive 
PET      1.02(0.72,1.45)   1.02(0.72,1.44)  0.68(0.45,1.04)   0.70(0.46,1.05)  0.95(0.82,1.11)   0.96(0.82,1.11)  
CSF      1.05(0.76,1.44)   1.05(0.76,1.44)  0.82(0.55,1.22)   0.83(0.55,1.24)  0.88(0.76,1.03)   0.89(0.76,1.04)  
Visuo- 
spatial 
PET 1.36(1.22,1.52) *** *** 1.33(1.19,1.48) *** 0.92(0.59,1.45)   0.89(0.56,1.41)       1.30(1.15,1.49) *** *** 1.25(1.10,1.43) ** 
CSF 1.38(1.23,1.55) *** *** 1.34(1.19,1.50) *** 1.34(0.93,1.93)   1.35(0.95,1.93)       1.21(1.07,1.37) ** ** 1.16(1.03,1.31) * 
MRI MTA 
PET           0.77(0.48,1.24)   0.75(0.47,1.20)       
CSF           1.09(0.69,1.73)   0.98(0.62,1.54)       
MRI PCA 
PET           0.84(0.47,1.51)   0.85(0.48,1.51)       
CSF           0.74(0.41,1.32)   0.75(0.42,1.32)       
MRI Fazekas 
PET      0.98(0.53,1.83)   0.92(0.50,1.71)            
CSF      1.38(0.79,2.41)   1.25(0.72,2.16)            
MRI 
microbleeds 
PET 1.91(1.21,3.01) ** ** 1.59(1.01,2.50)  2.17(0.75,6.30)   1.84(0.68,4.99)  1.32(0.52,3.32)   1.11(0.47,2.62)       
CSF 1.51(0.96,2.39)   1.35(0.86,2.10)  1.49(0.52,4.25)   1.32(0.49,3.52)  1.06(0.42,2.65)   0.98(0.41,2.32)       
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Table 3. Amyloid-adjusted predictive value of patient features for amyloid status based on PET or CSF 
 
 
*** - p<0.001, ** - p<0.01, * - p<0.05. P-values indicate the significance of the patient feature in the model. Uncorrected p-values and corrected p-values are reported per model, additionally 
corrected p-values for imputed data. False discovery rate (FDR) correction was performed for multiple comparisons. Cognitive scores have been multiplied by -1, therefore lower scores usually 
indicate higher odds ratios for amyloid positivity 
    TOTAL SCD MCI DEMENTIA 
          Imputed       Imputed       Imputed        Imputed  
Predictor 
Out- 
come 
Odds ratio 
(95% CI) 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR 
Odds ratio 
(95% CI) 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR Odds ratio 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR Odds ratio 
p 
unc 
p 
FDR 
Odds ratio 
(95% CI) 
p 
FDR 
Age 
PET 1.03(1.00,1.06)     1.03(1.00,1.06)   1.04(0.99,1.10)     1.04(0.99,1.1)   0.97(0.91,1.04)     0.97(0.91,1.04)             
CSF 0.99(0.96,1.02)     0.99(0.96,1.02)   1.02(0.97,1.07)     1.02(0.97,1.07)   0.98(0.92,1.04)     0.98(0.92,1.04)             
Sex, F 
PET           1.17(0.49,2.77)     1.17(0.49,2.77)   2.27(0.75,6.90)     2.27(0.75,6.90)   1.93(1.04,3.58) *   1.93(1.04,3.58)   
CSF           1.76(0.80,3.90)     1.76(0.8,3.9)   1.11(0.37,3.35)     1.11(0.37,3.35)   0.84(0.44,1.59)     0.84(0.44,1.59)   
Education 
PET 1.06(0.89,1.27)     1.07(0.89,1.27)                       1.16(0.9,1.49)     1.18(0.92,1.51)   
CSF 1.00(0.84,1.19)     1.00(0.84,1.19)                       1.15(0.89,1.50)     1.14(0.88,1.48)   
APOE E4 
PET 2.58(1.65,4.03) *** *** 2.52(1.62,3.93) *** 1.54(0.62,3.78)     1.56(0.63,3.82)   9.44(2.93,30.39) *** ** 8.79(2.72,28.41) ** 2.22(1.20,4.09) * * 2.14(1.16,3.95) * 
CSF 2.30(1.47,3.60) *** ** 2.28(1.45,3.57) ** 3.07(1.33,7.07) **   3.01(1.3,6.94)   1.85(0.58,5.92)     1.85(0.58,5.88)   2.00(1.06,3.78) *   2.00(1.07,3.75)   
CSF tau 
PET 
1.003  
(1.003,1.004) *** *** 
1.003  
(1.003,1.004) *** 
1.003  
(1.001,1.005) ** * 
1.003  
(1.001,1.005) * 
1.008  
(1.004,1.012) *** *** 1.008 (1.004,1.012) ** 
1.003  
(1.002,1.004) *** *** 
1.003  
(1.002,1.004) *** 
CSF 
1.001  
(1.000,1.002) ** * 
1.001  
(1.000,1.002) * 
1.002  
(1.000,1.003)     
1.001  
(1.000,1.003)   
0.999  
(0.997,1.001)     0.999 (0.997,1.001)   
1.001  
(1.000,1.002)     
1.001  
(1.000,1.002)   
CSF p-tau 
PET 1.04(1.03,1.05) *** *** 1.04(1.03,1.05) *** 1.02(1.01,1.04) ** * 1.03(1.01,1.04) * 1.05(1.02,1.07) *** ** 1.05(1.02,1.07) ** 1.04(1.03,1.05) *** *** 1.04(1.03,1.05) *** 
CSF 1.01(1.00,1.02) *   1.01(1.00,1.02)   1.01(1.00,1.03)     1.01(0.99,1.02)   0.99(0.98,1.01)     0.99(0.98,1.01)   1.01(1.00,1.02)     1.01(1.00,1.02)   
MMSE 
PET 1.11(1.05,1.17) *** ** 1.10(1.04,1.17) ** 0.93(0.80,1.10)     0.93(0.79,1.09)                       
CSF 1.10(1.04,1.16) ** ** 1.10(1.04,1.16) ** 1.21(1.03,1.41) *   1.19(1.02,1.38)                       
Memory 
PET 1.22(1.12,1.34) *** *** 1.22(1.12,1.33) *** 0.99(0.69,1.42)     1.01(0.7,1.46)   1.25(0.96,1.64)     1.27(0.97,1.65)   1.18(1.05,1.32) ** * 1.17(1.05,1.31) * 
CSF 1.09(1.00,1.19) *   1.09(1.01,1.19)   1.23(0.87,1.75)     1.21(0.85,1.72)   0.96(0.71,1.30)     0.92(0.68,1.25)   1.00(0.89,1.11)     1.01(0.91,1.12)   
Language 
PET                     0.23(0.08,0.68) ** * 0.32(0.10,1.01)             
CSF                     1.59(0.77,3.27)     1.37(0.63,2.98)             
Executive 
PET           0.99(0.67,1.48)     0.99(0.67,1.47)   0.61(0.33,1.12)     0.62(0.34,1.14)   1.11(0.88,1.40)     1.10(0.87,1.39)   
CSF           1.05(0.71,1.55)     1.05(0.72,1.54)   1.18(0.64,2.17)     1.17(0.64,2.15)   0.81(0.64,1.03)     0.82(0.64,1.04)   
Visuo-spatial 
PET 1.19(1.03,1.37) * * 1.17(1.03,1.34) * 0.77(0.49,1.22)     0.73(0.46,1.18)             1.32(1.10,1.59) ** * 1.28(1.07,1.53) * 
CSF 1.20(1.04,1.39) * * 1.16(1.01,1.34)   1.53(0.99,2.38)     1.58(1.01,2.45)             0.99(0.84,1.17)     0.97(0.83,1.13)   
MRI MTA 
PET                     0.55(0.28,1.05)     0.58(0.30,1.09)             
CSF                     1.78(0.87,3.63)     1.52(0.76,3.03)             
MRI PCA 
PET                     1.09(0.48,2.46)     1.11(0.50,2.48)             
CSF                     0.69(0.30,1.58)     0.69(0.31,1.52)             
MRI Fazekas 
PET           0.76(0.36,1.62)     0.7(0.33,1.5)                       
CSF           1.56(0.83,2.96)     1.48(0.78,2.78)                       
MRI 
microbleeds 
PET 2.08(1.07,4.03) *   1.75(0.90,3.41)   2.15(0.60,7.67)     1.94(0.55,6.86)   1.62(0.43,6.12)     1.30(0.36,4.68)             
CSF 0.89(0.46,1.73)     0.88(0.46,1.71)   1.01(0.29,3.57)     0.91(0.26,3.17)   0.75(0.20,2.81)     0.81(0.22,2.94)             
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Education
Sex
Age
0.000 0.006 0.012 0.018 0.024
PET
CSF
D. Dementia (n = 447)
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